Get our Free Patent Expiration Newsletter

Serving hundreds of leading biopharmaceutical companies globally:

Harvard Business School
Accenture
Chinese Patent Office
Express Scripts
McKinsey
Teva

Generated: September 18, 2019

DrugPatentWatch Database Preview

Patent: 9,326,974

  Try a free trial


See Plans and Pricing

« Back to Dashboard

Summary for Patent: 9,326,974
Title:Methods and related compositions for the treatment of cancer
Abstract: A method of treatment and/or prevention of cancer comprises administering agents which cause increased intracellular granularity in cancer cells, at least in an amount sufficient to inhibit proliferation of such cells and preferably in an amount sufficient to lead to cancer cell death. The method is particularly directed to refractory cancer, particularly hormone refractory prostate cancer. The agents identified cause increased intracellular granularity in the cancer cells, and also convert adherent cancer cells to non-adherent cancer cells, leading to cancer cell death. Using the present invention, cancer cells undergo increased intracellular granularity at relatively low agent concentrations, while also inhibiting cell proliferation. Increased concentrations lead to conversion of adherent cancer cells to non-adherent cancer cells, then to cell death. While the exact mechanism of cancer cell degradation and death is not completely understood, the treated cancer cells, including refractory prostate cancer cells, give indications of cell death through an autophagic mechanism. Pharmaceutical compositions related to the presently disclosed methods are also disclosed.
Inventor(s): Thompson; Todd A. (Albuquerque, NM), Mackenzie; Debra (Albuquerque, NM), Oprea; Tudor I. (Albuquerque, NM), Sklar; Larry A. (Albuquerque, NM), Edwards; Bruce S. (Albuquerque, NM), Haynes; Mark (Albuquerque, NM)
Assignee: STC.UNM (Albuquerque, NM)
Application Number:14/449,957
Patent Claims:see list of patent claims

Details for Patent 9,326,974

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Merck ELSPAR asparaginase VIAL 101063 001 1978-01-10   Try a Free Trial STC.UNM (Albuquerque, NM) 2028-06-05 RX search
Schering INTRON A interferon alfa-2b VIAL 103132 001 1986-06-04   Try a Free Trial STC.UNM (Albuquerque, NM) 2028-06-05 RX search
Schering INTRON A interferon alfa-2b VIAL 103132 002 1986-06-04   Try a Free Trial STC.UNM (Albuquerque, NM) 2028-06-05 RX search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Subscribe to access the full database, or try a Free Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

McKesson
Federal Trade Commission
Argus Health
Accenture
AstraZeneca
Merck

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.